The Illinois market is centred on Chicago, where a handful of experts at large, well-resourced national firms cream off the biggest and most important cases; representation below this level is provided by a group of high-quality litigators, often with broad IP and patent practices.
James Ferguson of Mayer Brown has handled an “incredibly impressive” and diverse portfolio of life sciences cases. He represents branded pharmaceutical players in Hatch-Waxman litigation and recently appeared for Unimed in a dispute against Watson Laboratories and Paddock Laboratories. He also represents major pharmaceutical companies such as Abbott in patent litigation relating to new biological entities. The third portion of his life sciences practice concerns work with medical device companies. Clients are impressed by his “ability to grasp and communicate highly technical concepts”. Chair of the IP department at Sidley Austin is David Pritikin, who maintains a broad litigation practice across the full spectrum of IP matters, including highprofile Hatch-Waxman cases; sources say he is an “extremely capable litigator“.
Heading up the chemical group at Brinks Hofer Gilson & Lione is Thomas Filarski, who maintains a broad litigation and general life sciences practice. At Leydig Voit & Mayer, Robert Green handles a wide array of IP work for a broad range of clients, with a focus on pharmaceutical matters; he represents Astellas Pharma, Lupin, Dexcel Pharma and others. Also at the firm is John Kilyk, “a very strong IP litigator” whose core expertise lies in the biotechnology and pharmaceutical fields. Joseph Mahoney of Mayer Brown combines “deep technical knowledge” with patent litigation skills; he is recognised for his work representing innovator pharmaceutical companies. At McAndrews Held & Malloy, Edward Mas maintains an IP-focused trial and appellate practice; clients extol his “extensive experience in life sciences”.